Difference between revisions of "Glucarpidase (Voraxaze)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated package insert links) |
||
Line 1: | Line 1: | ||
'''FDA approved 1/17/2012''' | '''FDA approved 1/17/2012''' | ||
==General information== | ==General information== | ||
− | Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf Glucarpidase (Voraxaze) package insert]</ref><ref>[http:// | + | Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf Glucarpidase (Voraxaze) package insert at FDA.gov]</ref><ref>[http://www.btgplc.com/document/442 Glucarpidase (Voraxaze) package insert at BTG]</ref><ref>[[Media:Glucarpidase.pdf|Glucarpidase (Voraxaze) package insert (locally hosted backup)]]</ref><ref>[http://www.btgplc.com/products/specialty-pharmaceuticals/voraxaze Glucarpidase (Voraxaze) manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Line 8: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
− | Brief patient counseling information can be found on the last page of the [http://www. | + | *[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]</ref> |
+ | *Brief patient counseling information can be found on the last page of the [http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf#page=11 package insert].<ref name="insert"></ref> | ||
==References== | ==References== | ||
<references/> | <references/> |
Revision as of 18:00, 15 July 2012
FDA approved 1/17/2012
General information
Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Glucarpidase (Voraxaze) patient drug information (UpToDate)[5]
- Brief patient counseling information can be found on the last page of the package insert.[1]